The groundbreaking success of the copyright undeniably revolutionized the pharmaceutical landscape, but betting in companies heavily reliant on unbranded versions presents a challenging picture. Despite early earnings were substantial, the expiration of patents and the rise of discounted alternatives have eroded market share. Therefore, a thorough